CD274 and non-small cell lung carcinoma: Our study is the first to demonstrate that LCT following effective first-line PD-1/PD-L1 inhibitors treatment improved PFS and OS mainly in NSCLC patients with 1–2 residual sites or high PD-L1 expression.